Latest Conference Articles

March 5th 2021, 9:26pm

PER® Miami Breast Cancer Conference

Although there is evidence to suggest that surgery with or without radiation therapy can be utilized in some patients with stage IV breast cancer who have experienced locoregional progression or symptoms to some success with regard to locoregional disease control, most patients will not achieve a survival benefit.

March 5th 2021, 7:42pm

PER® Miami Breast Cancer Conference

CDK4/6 inhibitors plus aromatase inhibitors have shown benefit as frontline treatment for patients with hormone receptor–positive, HER2-negative advanced breast cancer, but more data are needed to determine their role as adjuvant therapy before they are adopted into standard practice for patients with early-stage disease.

March 5th 2021, 3:08am

PER® Miami Breast Cancer Conference

Adam M. Brufsky, MD, PhD, discusses the role of neoadjuvant chemotherapy in triple-negative breast cancer.

March 5th 2021, 2:52am

PER® Miami Breast Cancer Conference

Patrick I. Borgen, MD, discusses eliminating the use of opioids in patients with breast cancer.

March 2nd 2021, 9:35pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Genomic sequencing is a critical step in informing the prognosis of patients with acute lymphoblastic leukemia and more information regarding specific subgroups of ALL, such as lineage ambiguous ALL, could pave the way for more personalized therapies for patients.

March 2nd 2021, 9:25pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Although it is too soon to tell whether the addition of a CD20-directed antibody to novel agents in relapsed/refractory follicular lymphoma should become standard practice, it is clear that immunotherapy could represent the next paradigm shift.

March 2nd 2021, 9:03pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

With an increased understanding of disease biology, several approaches are under examination to optimize the management of patients with graft-versus-host disease.

March 2nd 2021, 12:13am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Minimal residual disease has helped to predict relapse in numerous leukemia subtypes, with novel testing methods helping to identify the biomarker at a higher sensitivity than ever before.

March 1st 2021, 11:22pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

The treatment landscape of Waldenström macroglobulinemia is becoming increasingly complex with second-generation BTK inhibitors; however, the combination of bendamustine and rituximab remains the frontline standard of care for this patient population.

March 1st 2021, 7:46pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Immune therapy has evolved rapidly in multiple myeloma, and the field is on the verge of major improvements in outcomes.

March 1st 2021, 3:45pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Although scientific advances in hematology and oncology have been extraordinary, the US health care system faces significant challenges in ensuring that patients receive high-quality, cost-effective care.

February 28th 2021, 11:30am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Several options have emerged for patients with acute myeloid leukemia who are not candidates to receive chemotherapy, with venetoclax-based regimens chief among them.

February 27th 2021, 11:30am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

February 26th 2021, 10:27pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

February 26th 2021, 9:06pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Rituximab plus CHOP is not a suitable frontline treatment regimen for all patients with diffuse large B-cell lymphoma, explained Andre H. Goy, MD, who specified that patients with a high-risk International Prognostic Index, elderly patients, and patients with high-risk molecular subtypes require alternative treatment.

February 26th 2021, 12:53am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

February 26th 2021, 12:01am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Treatment with chimeric antigen receptor T cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.

February 25th 2021, 11:30pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.

February 25th 2021, 11:21pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Andrew Ip, MD, MS, discusses the challenges of treating patients with hematologic malignancies and COVID-19.

February 25th 2021, 11:06pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Carlos del Rio, MD, discusses factors to consider when selecting between available vaccines for COVID-19.